Novo Nordisk AS (HAM:NOVA)
€ 41.8 -0.20 (-0.48%) Market Cap: 185.04 Bil Enterprise Value: 201.74 Bil PE Ratio: 11.60 PB Ratio: 6.95 GF Score: 81/100

Preliminary Q2 2025 Novo Nordisk A/S Earnings and to Discuss Changes in Executive Leadership Call Transcript

Jul 29, 2025 / 12:30PM GMT
Jacob Rode;S;Head of Investor Relations
Novo Nordisk A

/-

Welcome to this conference call regarding the changes to Novo Nordisk executive leadership as well as the lowering of the financial outlook for 2025 that we announced today.

My name is Jacob Rode and I'm the Head of Investor Relations at Novo Nordisk. With me today I have Helge Lund, Chair of the Board of Directors of Novo Nordisk; CEO of Novo Nordisk, Lars Fruergaard Joergensen; Chief Financial Officer, Karsten Munk Knudsen; Executive Vice President, US Operations, David Moore; and finally Executive Vice President, International Operations, and incoming CEO as of August 7, Mike Doustdar. All speakers will be available for the Q&A.

Today's announcements are available on our website, novonordisk.com. Please note that the call is being webcasted live and a recording will be made available on our website too. The call is scheduled to last for a maximum of 45 minutes. Next slide, please.

The presentation is structured as outlined on slide 2. We will briefly cover both of today's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot